Phase Ib/IIa trial is to evaluate the efficacy of VES001 in asymptomatic patients with gene mutations that cause frontotemporal dementia A total of six participants have been enrolled in the trial ...
Phase Ib/IIa study found VES001, the first oral therapy being tested in FTD, led to >95% mean increase in progranulin levels in CSF, compared to baseline Topline results indicate VES001 normalises ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results